NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the third quarter 2025 ending September 30, 2025 on Friday, November 7, 2025 after the close of the US market.
The press release will be available in the Investors section of Cellectis’ website: https://www.cellectis.com/en/investors/press-releases/
Read more on Bluefield Daily Telegraph
This news is powered by Bluefield Daily Telegraph 
